GLM101

Glycomine, Inc. · Phase 2 active Small molecule

At a glance

Generic name	GLM101
Sponsor	Glycomine, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients (PHASE2)
A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG (PHASE2, PHASE3)
24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GLM101 CI brief — competitive landscape report
GLM101 updates RSS · CI watch RSS
Glycomine, Inc. portfolio CI